Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01740791 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
A Phase 1 study of Chronic Hepatitis C Virus, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
- 10
- Study locations
NCT01740791 is a Phase 1 study of Chronic Hepatitis C Virus that has completed, run by Gilead Sciences. The registered enrollment target is 103 participants, below the 329-participant average among 3 other Chronic Hepatitis C Virus trials with a reported enrollment target (69% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT01740791, a Phase 1 study of Chronic Hepatitis C Virus, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Velpatasvir
Study Locations (10)
Florida
- Avail Clinical Research, LLC - DeLand
- Orlando Clinical Research Center - Orlando
California
- West Coast Clinical Trials, LLC - Costa Mesa
Missouri
- Kansas City Gastroenterology and Hepatology - Kansas City
New Jersey
- CRI Worldwide, LLC - Marlton
Pennsylvania
- CRI Worldwide, LLC - Philadelphia
Tennessee
- New Orleans Center for Clinical Research-Knoxville - Knoxville
Texas
- Alamo Medical Research - San Antonio
Washington
- Charles River Clinical Services Northwest, Inc. - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2012-11-06 |
| Est. Completion | 2014-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01740791
The ClinicalTrials.gov registry entry for NCT01740791 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 329-participant average among 3 other Chronic Hepatitis C Virus trials with a reported enrollment target (69% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis C Virus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01740791 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT01740791 about?
NCT01740791 is a clinical study titled "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection". The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.
What is the current status of trial NCT01740791?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2012-11-06. Estimated completion is 2014-01-24.
What conditions does trial NCT01740791 study?
This clinical trial studies the following conditions: Chronic Hepatitis C Virus.
What interventions are being tested in trial NCT01740791?
The interventions under investigation include: Placebo (DRUG), Velpatasvir (DRUG).
Who is sponsoring clinical trial NCT01740791?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01740791 being conducted?
This trial has 10 study locations across California, Florida, Missouri, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
COMPLETED · Phase 3
-
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
COMPLETED · Phase 2
-
VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.